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Introduction:
Abnormal development of antigen presenting cells (APCs) can result in immunodeficiency and autoimmune disease. APCs include macrophages, B cells, and dendritic cells (DCs) and are critical for mediating adaptive immunity to foreign antigens as well as inducing tolerance to self-antigens. At steady state, macrophages are generated from monocytes, and classic DCs are derived from their precursor pre-cDCs and common DC progenitors (CDPs) (1) (2) (3) (4) (5) (6) . These cells are all generated from upstream macrophage-DC-restricted progenitor cells (MDP) (7) (8) (9) , which are themselves derived from less lineage-restricted common myeloid progenitors (CMPs (1) . The entire populations of hematopoietic cells originate from pluripotent hematopoietic stem cells (HSC) in the bone marrow (see figure 7A ). Despite recent advances, the cellular factors that regulate the progression of HSCs to the development of APCs remain largely uncharacterized.
Cap 'n' collar (CNC) proteins are evolutionarily conserved factors that are known to be essential for the resolution of oxidative stress (10) . In Caenorhabditis elegans, the CNC protein SKN-1 regulates longevity (11, 12) . In mammals, there are six members within the CNC family (p45, Nrf1, Nrf2, Nrf3, Bach1, and Bach2) that heterodimerize with small Maf proteins (MafK, MafG, MafF) to direct either gene induction or repression (13) .
For instance, whereas the co-occupancy of p45 and MafK at genome elements activates transcription, binding of a Bach1 and MafK heterodimer to these elements results in gene repression (14) . Many different CNC and Maf heterodimers are formed (15) , causing the biology of CNC and Maf members to be complex. Whereas
Nrf1
-/-mice (16) are anemic and suffer embryonic or postnatal lethality, ablation of p45 in mice leads to defective platelet production (17) . While deletion of Bach2 in mice caused impaired antibody class switching (18) , disruption of Nrf2 resulted in a neurodegenerative disorder and autoimmune disease (19) (20) (21) .
Deciphering the physiological role of some of the CNC:Maf proteins has also proven to be challenging because of the potential functional redundancy amongst them (22, 23) .
The CNC:Maf network has been associated with a myriad of human pathologies, including those of the skin, respiratory system, and hematopoietic system (10, 15, 24) . Thus, drug therapy involving the CNC pathway is actively being studied in human for cancer chemoprevention, inflammatory diseases, and autoimmune diseases (for review (10) ). For example, the fumaric acid ester dimethylfumarate (DMF), which exerts neuroprotection by inducing Nrf2 expression, is currently in a phase III clinical trial as an orally active effective treatment of human multiple sclerosis with limited side effects (25, 26) . Thus, deciphering the functions of the individual CNC subunits will not only be crucial to unraveling the overlapping and unique functions of these proteins, it will also provide insights to the potential of targeting CNC proteins for therapy against relevant diseases. In particular, the CNC member Bach1 is up-regulated in fetal Down Syndrome (DS)
brain (27) . Bach1 expression is also significantly higher in DS-acute megakaryoblastic leukemic patients (AMKL) than non-DS-AMKL patients (24). The best-known effect of Bach1 on transcriptional regulation is its repression of heme oxygenase-1 (HO-1) (14, 28, 29) , which is a pivotal enzyme for metabolism of heme for iron reutilization and resolving oxidative stress (30, 31) . HO-1 inhibits the development of autoimmune neuroinflammation likely by suppressing APC function and reducing the accumulation of self-reactive T cells in
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 4 the central nervous system (32) . At steady state, Bach1 directly binds to the HO-1 promoter to repress expression. During high heme concentration conditions, heme associates with Bach1 and relieves this repressive effect and results in HO-1 up-regulation. In theory, the Bach1:HO-1 pathway serves as a feedback loop to maintain homeostasis of heme and prevent oxidative stress (33) . However, little is known about the physiological function of the Bach1:HO-1 pathway and its potential role in disease pathology.
In this study, we examine whether Bach1 plays a role in autoimmune disease development and normal immune function. We report here that disruption of Bach1 (14) alone results in partial protection from the development of autoimmune diseases using the murine model of human multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE). This phenotype is accompanied by defective peripheral T-cell responses in mice. However, deleting Bach1 does not appear to affect T-cell function intrinsically but rather impaired the development of certain antigen presenting cells (APC) subsets, specifically macrophages and DCs. We performed genome wide analyses and identified a panel of Bach1 target genes that might be important for APC development. Of these genes, HO-1 was highly up-regulated upon deleting Bach1 in APCs.
To determine the significance of HO-1 up-regulation, we generated Bach1
- 
Bone Marrow Reconstitution
C57bl/6 recipient animals were irradiated with 1,200 rad. of cesium. Ten million WT or Bach1 -/-BMCs were injected into the lethally irradiated animals. Six to eight weeks post reconstitution, the recipient mice were sacrificed or immunized.
Enzyme Linked Immunosorbent Assays (ELISAs)
ELISAs for T-cell cytokines were performed as described by manufacturer. For the MOG 35-55 specific-IgG, ELISA, MOG (2ug/mL) peptide was coated onto a 96-well plate overnight. Serially diluted serum were loaded on the plate and quantified according to the protocol described by manufacturer (Bethyl Laboratories, catalog #: E90-131). and 400ug CFA and 600ng of pertussis toxin (PT). The same amount of PT was injected 22-26 hours later. The following disease scoring system was used: 0.5=partial limp tail, 1=complete limp tail, 2=wobbly walk, 2.5=one leg paralysis, 3=two leg paralysis, 3.5=three leg paralysis, 4=moribund, 5=death. One month after EAE induction, total spinal cord was harvested, stained with fluorochrome-conjugated antibodies, and subjected to flow cytometric analyses to quantify the ratio of immune cellular infiltrates. FACS plots were forward and side scatter gated for hematopoietic cells.
Ovalbumin immunization and T-cell recall experiments
Generation of BM-DCs and BMMs
Cells harvested from the bone marrow were plated in medium containing 20ng/mL of G-MCSF. On day four, GMCSF-containing medium was replenished. Three days later, all the surviving cells were harvested and subjected to flow cytometric analyses. To generate BMMs, bone marrow cells were cultured in media (Hyclone DMEM with 10% fetal bovine serum + pencillin/streptomycin) supplemented with 10ng/mL M-CSF. Six days later, the adherent macrophages were replenished with new media without M-CSF and experiments were performed.
Microarray Experiments
RNAs from WT and Bach1 -/-BMMs were submitted to University of California San Francisco microarray core facility for gene expression analyses. Briefly, Agilent 4x44K GE Mm arrays were used as platforms. Sample preparation, labeling, and array hybridizations were performed according to standard protocols from the UCSF Shared Microarray Core Facilities. Arrays were scanned using the Agilent microarray scanner and raw signal intensities were obtained using Feature Extraction v10.1 software (Agilent). All microarray data are available at ArrayExpress under accession number E-MEXP-3674.
Statistical Analyses
All P values were obtained using Student T-tests (unpaired two-tailed with 95% confidence interval) except for Figure 1A and Figure 1B , in which Two-Way ANOVA was used. Figure   1A ). Whereas 40% of tested WT animals developed complete hind leg paralysis and front leg paresis (clinical score ≥ 3.5), only 7% of Bach1 -/-mice developed such severe EAE symptom ( Figure 1B ). Of the animals tested, 91% of WT animals developed partial hind leg paralysis (clinical score of 2.5) whereas only 64% of Bach1 -/-animals exhibited this symptom. Of note, similar percentages of WT and Bach1 -/-animals (100% WT and 96% Bach1 -/-) developed mild EAE symptoms, marked by partial limp tail (clinical score of 0.5).
Collectively, these data demonstrated that Bach1 does not alter the incidence of EAE development but affects the severity of the disease. Consistent with this, the decrease in EAE severity corresponded to less weight loss in Bach1 -/-animals ( Figure 1C) ; we started measuring the weight of the animals after 12 days of EAE induction when signs of disease became noticeable. Moreover, Bach1 -/-mice were less capable of producing antibodies against MOG following immunization ( Figure 1D ), indicative of a reduced immune response in these mice.
The pathogenesis of EAE initiates with immune cell infiltration into the CNS. The lower inflammatory condition ( Figure 1D ) in Bach1 -/-mice suggested that these animals might be protected from EAE as a result of reduced penetration of immune cells into the CNS. To assess this, we harvested spinal cord from diseased animals and utilized flow cytometry to quantify the percent of infiltrating hematopoietic cells. Consistent with the lower disease severity, fewer APCs (CD45 + CD11b + MHC II + ) were found in the CNS of Bach1 -/-EAE animals ( Figure 2A ). This was a consequence of both less infiltration of peripheral dendritic cells ( Figure 2B) and fewer resident CNS microglia ( Figure 2C ), which proliferate upon EAE development (35) . In parallel to lower APCs, fewer infiltrating T-and B-cells were observed in the CNS of these animals ( Figure 2D-F) . Thus, during pathogenesis of EAE, ablation of Bach1 partially protects the CNS from immune cell infiltration and disease development.
Bach1 indirectly regulates T-cell mediated immune responses through controlling the steady state development of APCs
Our finding that deletion of Bach1 lowered infiltration of immune cell into the CNS during EAE pathogenesis, which is a T cell-mediated disease, provided the impetus for us to examine whether Bach1 regulates T cell effector responses in the periphery. To test this, we immunized wildtype and Bach1 -/-mice with ovalbumin (Ova), harvested the splenocytes, and re-stimulated the cultured splenocytes with vehicle or 8
Ova. Indeed, we observed that Ova stimulation of the Bach1 -/-splenocytes induced activation of fewer T cells Figure S2G ) and DC-committed precursors (5, 6) were lower in the bone marrow compartment of the mutant animals ( Figure 5H, Figure S2H ).
To determine whether the decrease in macrophage and DC populations in Bach1 -/-mice was responsible
for the lowered T cell responses described above (Figure 4) , we co-cultured splenocytes OTII CD4 + T cells in the presence of ovalbumin. A given number of Bach1 -/-splenocytes were less able than wild-type cells to induce an ovalbumin OTII CD4 + T cell response, which is consistent with Bach1 -/-mice having fewer APCs 9 ( Figure 5I) . Thus, our data indicates that Bach1 regulates the steady state level of specific populations of antigen presentation cells (APCs), limiting the magnitude of T cell responses.
Bach1 regulates development of APCs in a cell-autonomous manner
To investigate whether Bach1 functions within the hematopoietic compartment to activate APC development, we reconstituted lethally irradiated C57bl/6 WT recipient mice with WT or Bach1 -/-bone marrow cells (BMCs). The animals reconstituted with Bach1 -/-BMCs exhibited fewer macrophages and DCs in their spleens than those that received WT BMCs (Figure 5J, K) . To test whether Bach1 functions in other nonhematopoietic compartments to mediate DC development, WT and Bach1 -/-lethally irradiated mice were reconstituted with WT BMCs. Both recipient groups displayed a similar percentage of splenic macrophages and DCs (data not shown). Thus, Bach1 influences the development of these APCs by functioning within the hematopoietic compartment and not through other non-hematopoietic tissues. To examine whether Bach1
modulates APC development in a cell autonomous manner, BMCs were isolated and treated with GMCSF to generate dendritic cells in vitro (36) . Similar to our in vivo finding, BMCs harvested from Bach1 -/-mice produced fewer than 50% of the DCs generated by WT cells ( Figure 5L ). These in vitro experiments combined with our in vivo analyses imply that Bach1 is directly involved in the development of a subset of APCs through a cell-autonomous mechanism.
Identification of Bach1 targets
To provide insights into the mechanism and molecular pathways by which Bach1 regulates APC development, we performed whole genome gene expression microarray to identify gene targets regulated by Bach1 in bone marrow-derived macrophages (BMMs). Using this unbiased approach, we identified >300 genes differentially expressed in WT versus Bach1 -/-BMMs ( Figure 6A, Figure S3) . We validated by quantitative PCR a panel of genes up-regulated upon deletion of Bach1 -/-( Figure 6B) . In our microarrays, we found that the known direct Bach1 target HO-1 was the most highly up-regulated in Bach1 -/-BMMs (14, (28) (29) (30) (31) .
In addition, we also isolated previously unknown Bach1 targets, including Clec4n and Fl3a1 as well as Slc40a1/Fpn1. Slc40a1/Fpn1 was previously found to be concomitantly up-regulated with HO-1 after erythrophagocytosis (37) . Because HO-1 was identified in our microarrays as the most affected by Bach1 ablation, we next examined whether HO-1 could also be regulated by Bach1 in total primary BMCs. Indeed, we found that Bach1 -/-BMCs expressed significantly higher levels of HO-1 transcript ( Figure 6C) . Collectively, we identified a panel of Bach1 target genes that may be involved in Bach1-mediated APC development.
Deletion of HO-1 exacerbates the impaired APC development observed in Bach1 -/-mice
To investigate the mechanism by which Bach1 controls APC development, we examined the function of HO-1 up-regulated expression in the context of Bach1 ablation in hematopoietic development. We chose to study HO-1 because it has been previously identified as a direct target of Bach1 (14, 28, 29) and was identified 10 as the most affected gene in our microarrays by Bach1 deletion (Figure 6A, B) . To this end, we generated HO- than the expected 25% Mendelian distribution (Chi-square P < 0.0001). In the bone marrow compartment, we detected almost no macrophages in the HO-1 -/-Bach1 -/-mice ( Figure 6D) . The compound HO-1 -/-Bach1 -/-mice had even fewer DCs than Bach1 -/-animals ( Figure 6E) . It was reported that the generation HO-1 -/-mice was more successful in FVB than C57bl/6 background (38). Thus, we attempted to generate FVB HO-1 -/-mice through breeding heterozygotes; however, our breeding of HO-1 +/-pairs did not produce any HO-1 -/-pups (over 90 pups genotyped), precluding us from being able to examine APC development in mice with only HO-1 deletion. Nevertheless, our data demonstrated that the Bach1:HO-1 pathway is essential for macrophage development in the bone marrow and necessary for optimal development of DCs.
In addition, we also assessed whether we conclude that the Bach1:HO-1 pathway is an important event for committing pluripotent stem-progenitor cells to develop into APCs. In that study, it was found that deleting HO-1 in bone marrow-derived macrophages resulted in toxicity of these cells upon red blood cell phagocytosis, likely as a result of heme-overloaded toxicity. In our study, we found that the impaired APC development is also associated with the generation of their progenitors. Thus, it appears that HO-1 controls the number of APCs at a stage before as well as after development into mature
APCs. Collectively, we also identified a panel of previously unknown Bach1 targets. It will be interesting in the future to examine whether those genes also play a role in APC development. Potentially, Bach1 may regulate distinct or overlapping subsets of those genes for DC versus macrophage development.
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